Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

The Exam Room as Sanctuary – Caring for Undocumented Patients

Linares MA, Liauw D, Cervantes L. The Exam Room as Sanctuary - Caring for Undocumented Patients. N Engl J Med. 2026 Jul 11. doi: 10.1056/NEJMp2603126.[...]

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study

Htoo PT, Cho H, Paik JM, Bykov K, Everett BM, Glynn RJ, Shay C, Schmedt N, Wexler DJ, Patorno E. Cardiovascular outcomes of empagliflozin-GLP-1RA combination[...]

Coccidioidal peritonitis: A rare manifestation of disseminated coccidioidomycosis

Cheung N, Harmon R, Dietz RL Jr, Chandna S, Shoucri S. Coccidioidal peritonitis: A rare manifestation of disseminated coccidioidomycosis. IDCases. 2026 Jul 5;45:e02674. doi: 10.1016/j.idcr.2026.e02674.[...]